Chang T, Chen Y, Luo J, Zhang C, Chen S, Lin Z
Immunotargets Ther. 2025; 14:99-121.
PMID: 39990274
PMC: 11846490.
DOI: 10.2147/ITT.S492334.
Li D, Hu X, Tian Z, Ning Q, Liu J, Yue Y
Acta Pharmacol Sin. 2025; .
PMID: 39856433
DOI: 10.1038/s41401-024-01467-6.
Figueira M, Marques R, Cardoso H, Fonseca L, Duarte A, Silvestre S
Int J Mol Sci. 2024; 25(22).
PMID: 39596074
PMC: 11593390.
DOI: 10.3390/ijms252212006.
Jiang L, Qi X, Lai M, Zhou J, Yuan M, You J
Proc Natl Acad Sci U S A. 2024; 121(44):e2407904121.
PMID: 39432777
PMC: 11536108.
DOI: 10.1073/pnas.2407904121.
Aftab A, Sil S, Nath S, Basu A, Basu S
J Mol Evol. 2024; 92(6):669-684.
PMID: 39214891
DOI: 10.1007/s00239-024-10196-7.
Lnc PVT1 facilitates TGF-β1-induced human cardiac fibroblast activation in vitro and ISO-induced myocardial fibrosis in vivo through regulating MYC.
Wang J, Lv Z, Li P, Zhang Y, Li X, Shen D
Mol Cell Biochem. 2024; 480(3):1611-1625.
PMID: 38997507
DOI: 10.1007/s11010-024-05060-7.
Natural killer cells in cancer immunotherapy.
Wang D, Dou L, Sui L, Xue Y, Xu S
MedComm (2020). 2024; 5(7):e626.
PMID: 38882209
PMC: 11179524.
DOI: 10.1002/mco2.626.
C16, a PKR inhibitor, suppresses cell proliferation by regulating the cell cycle via p21 in colorectal cancer.
Hashimoto Y, Tokumoto Y, Watanabe T, Ogi Y, Sugishita H, Akita S
Sci Rep. 2024; 14(1):9029.
PMID: 38641657
PMC: 11031597.
DOI: 10.1038/s41598-024-59671-7.
UBE2C enhances temozolomide resistance by regulating the expression of p53 to induce aerobic glycolysis in glioma.
Zhou K, Wang D, Du X, Feng X, Zhu X, Wang C
Acta Biochim Biophys Sin (Shanghai). 2024; 56(6):916-926.
PMID: 38634120
PMC: 11214954.
DOI: 10.3724/abbs.2024033.
TGF-β signaling in health, disease, and therapeutics.
Deng Z, Fan T, Xiao C, Tian H, Zheng Y, Li C
Signal Transduct Target Ther. 2024; 9(1):61.
PMID: 38514615
PMC: 10958066.
DOI: 10.1038/s41392-024-01764-w.
Targeting MYC at the intersection between cancer metabolism and oncoimmunology.
Venkatraman S, Balasubramanian B, Thuwajit C, Meller J, Tohtong R, Chutipongtanate S
Front Immunol. 2024; 15:1324045.
PMID: 38390324
PMC: 10881682.
DOI: 10.3389/fimmu.2024.1324045.
PAF1c links S-phase progression to immune evasion and MYC function in pancreatic carcinoma.
Gaballa A, Gebhardt-Wolf A, Krenz B, Mattavelli G, John M, Cossa G
Nat Commun. 2024; 15(1):1446.
PMID: 38365788
PMC: 10873513.
DOI: 10.1038/s41467-024-45760-8.
Outsmarting trogocytosis to boost CAR NK/T cell therapy.
Ramezani F, Panahi Meymandi A, Akbari B, Tamtaji O, Mirzaei H, Brown C
Mol Cancer. 2023; 22(1):183.
PMID: 37974170
PMC: 10652537.
DOI: 10.1186/s12943-023-01894-9.
RUNX3 inactivates oncogenic MYC through disruption of MYC/MAX complex and subsequent recruitment of GSK3β-FBXW7 cascade.
Oei V, Chuang L, Matsuo J, Srivastava S, Teh M, Ito Y
Commun Biol. 2023; 6(1):689.
PMID: 37400551
PMC: 10317990.
DOI: 10.1038/s42003-023-05037-0.
Radiated tumor cell-derived microparticles effectively kill stem-like tumor cells by increasing reactive oxygen species.
Hu Y, Wan C, Yang X, Tian Y, Deng S, An D
Front Bioeng Biotechnol. 2023; 11:1156951.
PMID: 37342505
PMC: 10277801.
DOI: 10.3389/fbioe.2023.1156951.
Histone H3 lysine 27 crotonylation mediates gene transcriptional repression in chromatin.
Liu N, Konuma T, Sharma R, Wang D, Zhao N, Cao L
Mol Cell. 2023; 83(13):2206-2221.e11.
PMID: 37311463
PMC: 11138481.
DOI: 10.1016/j.molcel.2023.05.022.
Imatinib blocks tyrosine phosphorylation of Smad4 and restores TGF-β growth-suppressive signaling in BCR-ABL1-positive leukemia.
Wang L, Gu S, Chen F, Yu Y, Cao J, Li X
Signal Transduct Target Ther. 2023; 8(1):120.
PMID: 36959211
PMC: 10036327.
DOI: 10.1038/s41392-023-01327-5.
SNHG18 inhibits bladder cancer cell proliferation by increasing p21 transcription through destabilizing c-Myc protein.
Ke M, Sun N, Lin Z, Zhang P, Hu Y, Wu S
Cancer Cell Int. 2023; 23(1):48.
PMID: 36927398
PMC: 10018893.
DOI: 10.1186/s12935-023-02887-w.
Targeting p53 pathways: mechanisms, structures, and advances in therapy.
Wang H, Guo M, Wei H, Chen Y
Signal Transduct Target Ther. 2023; 8(1):92.
PMID: 36859359
PMC: 9977964.
DOI: 10.1038/s41392-023-01347-1.
The FACT-targeted drug CBL0137 enhances the effects of rituximab to inhibit B-cell non-Hodgkin's lymphoma tumor growth by promoting apoptosis and autophagy.
Lv Y, Du Y, Li K, Ma X, Wang J, Du T
Cell Commun Signal. 2023; 21(1):16.
PMID: 36691066
PMC: 9869543.
DOI: 10.1186/s12964-022-01031-x.